POXEL: Full exercice of the overallotment option

Regulatory News:

POXEL (Paris:POXEL) (Euronext - FR0012432516), an independent French biopharmaceutical company focused on the development of antidiabetic drugs, announces that Société Générale, acting in the name and on behalf of the Joint Lead Managers and Joint Bookrunners, has fully exercised the overallotment option on the 281,249 additional new shares at the offer price of €6.66 per share. Consequently, the total number of POXEL shares offered in the context of the IPO reaches 4,031,248 new shares. Furthermore, in accordance with Article 631-10 of the Autorité des Marchés Financiers’ ("AMF") General Regulations, Société Générale, acting as stabilizing agent, has conducted stabilizing operations on the POXEL shares (FR0012432516 – POXEL) that have started on February 6, 2015 and that closedon the same day, within a price range between €6.53 and €6.66 per share.

Settlement and delivery of the new shares issued from the full exercice of the overallotment option will take place on February 13, 2015.

Information available to the Public - Copies of the prospectus in the French language (the "Prospectus”), which received a visa from the AMF on January 22, 2015 under number 15-030, comprising a document de base registered with the AMF on January 7, 2015 under number I.15-001 (the "Document de Base”) and a securities note (the "Securities Note”) including the summary of the Prospectus, may be obtained free of charge at the company’s headquarter, (200 avenue Jean Jaurès, F-69007 Lyon, France) as well as from the company’s (www.poxel.com) and the AMF’s (www.amf-france.org) websites.

Risk factors - POXEL draws the public’s attention to the business-related risks described in Chapter 4 "Risk Factors” of the Document de Base and the offer-related risks described in Chapter 2 ”Offer-related Risk Factors” of the Securities Note.

About Poxel

POXEL, founded in 2009 in Lyon, is a French independent biopharmaceutical company developing anti-diabetic drug candidates discovered by Merck Serono Company, a major player in the type 2 diabetes market. POXEL product pipeline consists in several new compounds with strong potential aiming at a better disease evolution control and at reducing the complications. POXEL’s most advanced product, Imeglimin, is a new oral anti-diabetic agent whose efficacy has been tested in six phase 2 clinical trials and whose safety has been demonstrated on almost 800 patients. Ready to start its phase 3 trials in 2015, Imeglimin is expected to be the first anti-diabetic drug to target simultaneously and directly the two main type 2 diabetes defects in the liver, pancreas and muscles, by increasing insulin secretion in response to glucose and improving its efficiency. Imeglimin is protected by 16 patent families and has a unique and innovative mechanism of action regulating the mitochondrial bioenergetics in the cell. Imeglimin restores normal functioning of mitochondria, which are directly involved in type 2 diabetes pathophysiology. PXL770 is a direct AMPK activator ready for phase 1. AMP Kinase is a key enzyme in metabolic regulations, also activated by physical exercise. POXEL is located in the Lyon biotech cluster.

For more information, please visit www.poxel.com

Disclaimer

This press release and the information it contains does not, and will not, constitute a public offering to subscribe for or sell, nor the solicitation of an offer to subscribe for or buy, securities of POXEL in any jurisdiction other than France, including the United States, Canada, Australia or Japan. The publication or distribution of this communication may violate applicable laws and regulations in some jurisdictions. Therefore, persons in such countries and in countries in which this communication is broadcast, published or distributed must enquire about any local restrictions and comply with them.

In particular:

POXEL securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. POXEL does not intend to register any securities in the United States or to conduct a public offering of securities in the United States.

This communication is an advertisement and does not constitute a prospectus for the purposes of the Prospectus Directive (as defined below). A prospectus prepared pursuant to the Prospectus Directive has been published and scan be obtained in accordance with the Prospectus Directive.

In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a "Relevant Member State”), no action has been taken or will be taken to offer securities to the public that requires the publication of a prospectus in any Relevant Member State other than France. POXEL securities may be offered in a Relevant Member State (other than France) only (i) to any legal entity which is a qualified investor as defined in the Prospectus Directive; (ii) to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive); or (iii) in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided, that no such offer of securities shall require POXEL to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive.

For the purposes of this provision, the expressions "public offering” and "offer to the public” in relation to any POXEL securities in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe the securities, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State. The expression "Prospectus Directive” means Directive 2003/71/EC (as amended, including by Directive 2010/73/EU), and includes any relevant implementing measure in the Relevant Member State.

This communication is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) persons in the United Kingdom who have professional experience in matters related to investments and who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order”) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i), (ii) and (iii) above together being referred to as "relevant persons”). POXEL securities will only be available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire POXEL securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this release or any of its contents.

All statements other than statements of historical fact included in this press release about future events and are subject to (i) change without notice and (ii) factors beyond the POXEL’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target,” "believe,” "expect,” "aim,” "intend,” "may,” "anticipate,” "estimate,” "plan,” "project,” "will,” "can have,” "likely,” "should,” "would,” "could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond POXEL’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION DIRECTLY OR INDIRECTLY IN THE UNITED STATES, CANADA, AUSTRALIA AND JAPAN OR TO U.S. PERSONS.